Moelis (MC) 26.09 $MC
Moelis IPO Prices Below Range
at The Street - Wed Apr 16, 7:24AM CDT
Moelis & Co., the newest investment bank to hit public stock markets, priced its initial public offering below an expected range, raising less money for the Kenneth Moelis-run M&A advisory firm
Moelis & Company pricing of IPO of 6.5m class A common stock at USD25.00 per share
M2 - Wed Apr 16, 6:55AM CDT
An independent investment bank, Moelis & Company (NYSE:MC) priced its initial public offering (IPO) of 6,500,000 shares of its class A common stock at USD25.00 per share, it said today.
Moelis & Co. prices initial public offering at $25
AP - Wed Apr 16, 5:58AM CDT
NEW YORK (AP) — Moelis & Co. priced its initial public offering at $25 per share, which was below expectations.
Moelis & Company Announces Pricing of Initial Public Offering
Business Wire - Tue Apr 15, 5:15PM CDT
Moelis & Company (the "Company"
(NYSE:MC), a leading global independent investment bank, today announced the pricing of its initial public offering of 6,500,000 shares of its Class A common stock at a price to the public of $25.00 per share. Additionally, the Company has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of Class A common stock from the Company at the initial public offering price, less underwriting discounts and commissions. The Company's shares of Class A common stock are expected to begin trading on the New York Stock Exchange on April 16, 2014 under the ticker symbol "MC." The offering is expected to close on or about April 22, 2014 subject to satisfaction of customary closing conditions.
Forest Laboratories and Almirall Provide Update on the Fixed Dose Combination of Aclidinium and Formoterol in the U.S.
Business Wire - Wed Apr 09, 2:17AM CDT
Forest Laboratories, Inc. (NYSE:FRX) and Almirall, S.A. (ALM:MC) today announced that they have recently received feedback from the U.S. Food and Drug Administration (FDA) regarding the fixed dose combination of aclidinium and formoterol. Although no new issues have arisen, further discussion is needed with the Agency in order to address questions related to CMC (Chemistry, Manufacturing and Control) and a Type C meeting with the FDA is going to be requested, likely to be held during Q3 this year. Forest and Almirall believe that the fixed dose combination of aclidinium and formoterol can be an important therapy for U.S. COPD (Chronic Obstructive Pulmonary Disease) patients.
2012 SWOT Analysis of Sony Corporation Out Now
M2 - Thu Feb 21, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/fbpvcc/analysis_of_sony) has announced the addition of the "Analysis of Sony Corporation" company profile to their offering. Sony Corporation is engaged in the development, design, manufacture and sale of various kinds of electronic equipment, instruments and devices for consumer and industrial markets. The company develops, produces, manufactures and markets home-use game consoles and software. It is also engaged in the development, production, manufacture and distribution of recorded music in all commercial formats and musical genres. Sony develops, produces, manufactures, markets, distributes and broadcasts image-based software, including film, video and television. Analysis of Sony Corporation. A complete and comprehensive analysis of Sony, the world's leading electronics company, includes an overview of the electronics industry in the United States, a PEST Framework Analysis of the US Electronics Industry, and then moves on to analyzing
Moelis IPO Prices Below Range
at The Street - Wed Apr 16, 7:24AM CDT
Moelis & Co., the newest investment bank to hit public stock markets, priced its initial public offering below an expected range, raising less money for the Kenneth Moelis-run M&A advisory firm
Moelis & Company pricing of IPO of 6.5m class A common stock at USD25.00 per share
M2 - Wed Apr 16, 6:55AM CDT
An independent investment bank, Moelis & Company (NYSE:MC) priced its initial public offering (IPO) of 6,500,000 shares of its class A common stock at USD25.00 per share, it said today.
Moelis & Co. prices initial public offering at $25
AP - Wed Apr 16, 5:58AM CDT
NEW YORK (AP) — Moelis & Co. priced its initial public offering at $25 per share, which was below expectations.
Moelis & Company Announces Pricing of Initial Public Offering
Business Wire - Tue Apr 15, 5:15PM CDT
Moelis & Company (the "Company"
(NYSE:MC), a leading global independent investment bank, today announced the pricing of its initial public offering of 6,500,000 shares of its Class A common stock at a price to the public of $25.00 per share. Additionally, the Company has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of Class A common stock from the Company at the initial public offering price, less underwriting discounts and commissions. The Company's shares of Class A common stock are expected to begin trading on the New York Stock Exchange on April 16, 2014 under the ticker symbol "MC." The offering is expected to close on or about April 22, 2014 subject to satisfaction of customary closing conditions. Forest Laboratories and Almirall Provide Update on the Fixed Dose Combination of Aclidinium and Formoterol in the U.S.
Business Wire - Wed Apr 09, 2:17AM CDT
Forest Laboratories, Inc. (NYSE:FRX) and Almirall, S.A. (ALM:MC) today announced that they have recently received feedback from the U.S. Food and Drug Administration (FDA) regarding the fixed dose combination of aclidinium and formoterol. Although no new issues have arisen, further discussion is needed with the Agency in order to address questions related to CMC (Chemistry, Manufacturing and Control) and a Type C meeting with the FDA is going to be requested, likely to be held during Q3 this year. Forest and Almirall believe that the fixed dose combination of aclidinium and formoterol can be an important therapy for U.S. COPD (Chronic Obstructive Pulmonary Disease) patients.
2012 SWOT Analysis of Sony Corporation Out Now
M2 - Thu Feb 21, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/fbpvcc/analysis_of_sony) has announced the addition of the "Analysis of Sony Corporation" company profile to their offering. Sony Corporation is engaged in the development, design, manufacture and sale of various kinds of electronic equipment, instruments and devices for consumer and industrial markets. The company develops, produces, manufactures and markets home-use game consoles and software. It is also engaged in the development, production, manufacture and distribution of recorded music in all commercial formats and musical genres. Sony develops, produces, manufactures, markets, distributes and broadcasts image-based software, including film, video and television. Analysis of Sony Corporation. A complete and comprehensive analysis of Sony, the world's leading electronics company, includes an overview of the electronics industry in the United States, a PEST Framework Analysis of the US Electronics Industry, and then moves on to analyzing
